Deutsche Bank AG Reiterates “€56.00” Price Target for Stratec Biomedical AG (ETR:SBS)

Stratec Biomedical AG (ETR:SBS) has been assigned a €56.00 ($65.12) target price by investment analysts at Deutsche Bank AG in a report released on Tuesday, October 24th. The brokerage currently has a “neutral” rating on the stock. Deutsche Bank AG’s price target would suggest a potential downside of 10.14% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Oddo Securities set a €58.00 ($67.44) price target on Stratec Biomedical AG and gave the company a “neutral” rating in a report on Monday, July 24th. Berenberg Bank set a €59.00 ($68.60) price objective on Stratec Biomedical AG and gave the stock a “neutral” rating in a research report on Tuesday, July 25th. Kepler Capital Markets set a €66.00 ($76.74) price objective on Stratec Biomedical AG and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Warburg Research set a €62.00 ($72.09) price objective on Stratec Biomedical AG and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Finally, Oddo Bhf set a €58.00 ($67.44) price objective on Stratec Biomedical AG and gave the stock a “neutral” rating in a research report on Monday, October 23rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of €60.50 ($70.35).

Stratec Biomedical AG (SBS) traded down €0.31 ($0.36) during trading hours on Tuesday, hitting €62.32 ($72.47). The company had a trading volume of 5,304 shares, compared to its average volume of 18,300. Stratec Biomedical AG has a 12-month low of €41.30 ($48.02) and a 12-month high of €65.33 ($75.97).

COPYRIGHT VIOLATION WARNING: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://stocknewstimes.com/2017/11/11/deutsche-bank-ag-analysts-give-stratec-biomedical-ag-sbs-a-56-00-price-target.html.

About Stratec Biomedical AG

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply